Susquehanna International Group
ASND icon

Susquehanna International Group’s Ascendis Pharma A/S ASND Stock Holding History

Susquehanna International Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.87M Sell
38,800
-24,700
-39% -$5.54M ﹤0.01% 3295
2025
Q4 		$13.5M Buy
63,500
+1,900
+3% +$392K ﹤0.01% 2671
2025
Q3 		$12.2M Buy
61,600
+39,900
+184% +$7.44M ﹤0.01% 2780
2025
Q2 		$3.75M Sell
21,700
-48,100
-69% -$7.83M ﹤0.01% 4525
2025
Q1 		$10.9M Buy
69,800
+22,000
+46% +$3.14M ﹤0.01% 2423
2024
Q4 		$6.58M Sell
47,800
-104,400
-69% -$13.7M ﹤0.01% 3191
2024
Q3 		$22.7M Buy
152,200
+65,600
+76% +$8.86M ﹤0.01% 1704
2024
Q2 		$11.8M Buy
86,600
+26,600
+44% +$3.62M ﹤0.01% 2276
2024
Q1 		$9.07M Buy
60,000
+11,000
+22% +$1.57M ﹤0.01% 2737
2023
Q4 		$6.17M Sell
49,000
-8,000
-14% -$798K ﹤0.01% 3358
2023
Q3 		$5.34M Sell
57,000
-43,800
-43% -$4.1M ﹤0.01% 3404
2023
Q2 		$9M Buy
100,800
+70,000
+227% +$6.09M ﹤0.01% 2645
2023
Q1 		$3.3M Sell
30,800
-11,600
-27% -$1.33M ﹤0.01% 4137
2022
Q4 		$5.18M Buy
42,400
+31,200
+279% +$3.62M ﹤0.01% 3172
2022
Q3 		$1.16M Sell
11,200
-4,100
-27% -$389K ﹤0.01% 6262
2022
Q2 		$1.42M Sell
15,300
-69,500
-82% -$6.55M ﹤0.01% 5683
2022
Q1 		$9.95M Buy
84,800
+47,000
+124% +$5.44M ﹤0.01% 2564
2021
Q4 		$5.08M Sell
37,800
-10,700
-22% -$1.59M ﹤0.01% 3708
2021
Q3 		$7.73M Sell
48,500
-25,800
-35% -$3.53M ﹤0.01% 3256
2021
Q2 		$9.77M Buy
74,300
+27,400
+58% +$3.65M ﹤0.01% 2949
2021
Q1 		$6.04M Buy
46,900
+32,200
+219% +$4.89M ﹤0.01% 3554
2020
Q4 		$2.45M Sell
14,700
-23,500
-62% -$3.89M ﹤0.01% 4678
2020
Q3 		$5.89M Sell
38,200
-73,400
-66% -$10.6M ﹤0.01% 2841
2020
Q2 		$16.5M Sell
111,600
-14,300
-11% -$1.96M ﹤0.01% 1609
2020
Q1 		$14.2M Sell
125,900
-23,900
-16% -$3.11M ﹤0.01% 1434
2019
Q4 		$20.8M Sell
149,800
-26,700
-15% -$2.97M 0.01% 1377
2019
Q3 		$17M Buy
176,500
+37,500
+27% +$4.18M 0.01% 1464
2019
Q2 		$16M Buy
139,000
+37,000
+36% +$4.43M 0.01% 1461
2019
Q1 		$12M Buy
102,000
+47,700
+88% +$4.18M ﹤0.01% 1569
2018
Q4 		$3.4M Sell
54,300
-7,200
-12% -$452K ﹤0.01% 2755
2018
Q3 		$4.36M Buy
61,500
+4,800
+8% +$330K ﹤0.01% 2846
2018
Q2 		$3.77M Buy
+56,700
New +$3.73M ﹤0.01% 3076

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's ASND Position: Q1 2026 in Review

Susquehanna International Group reduced its Ascendis Pharma A/S (ASND) stake by 94% in Q1 2026, selling an estimated $99.3M and leaving 28,062 shares worth $6.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3824.

Susquehanna International Group first reported a position in ASND in Q2 2018 and has held it in 24 quarters since. The position peaked at $100M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • Susquehanna International Group held 28,062 shares of Ascendis Pharma A/S worth $6.42M as of Q1 2026.
  • Susquehanna International Group sold 442,889 Ascendis Pharma A/S shares in Q1 2026, an estimated $99.3M.
  • Ascendis Pharma A/S made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3824 holding.
  • Susquehanna International Group first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 24 quarters since.
  • Susquehanna International Group's Ascendis Pharma A/S position peaked at $100M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.